Impact of Preoperative Transcatheter Arterial Chemoembolization (TACE) on Postoperative Long-term Survival in Patients with Nonsmall Hepatocellular Carcinoma: a Propensity Score Matching Analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Feb 9

PMID 38336712

Authors

Run Hu

Jie Xu

Hongxiang Wang

Jiaguo Wang

Kai Lei

Xiaoping Zhao

Huizhi Zhang

Ke You

Zuojin Liu

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this propensity score matching (PSM) analysis was to compare the effects of preoperative transcatheter arterial chemoembolization (TACE) and non-TACE on the long-term survival of patients who undergo radical hepatectomy.

Methods: PSM analysis was performed for 387 patients with hepatocellular carcinoma (HCC) (single > 3 cm or multiple) who underwent radical resection of HCC at our centre from January 2011 to June 2018. The patients were allocated to a preoperative TACE group (n = 77) and a non-TACE group (n = 310). The main outcome measures were progression-free survival (PFS) and overall survival (OS) since the treatment date.

Results: After PSM, 67 patients were included in each of the TACE and non-TACE groups. The median PFS times in the preoperative TACE and non-TACE groups were 24.0 and 11.3 months, respectively (p = 0.0117). The median OS times in the preoperative TACE and non-TACE groups were 41.5 and 29.0 months, respectively (p = 0.0114). Multivariate Cox proportional hazard regression analysis revealed that preoperative TACE (hazard ratio, 1.733; 95% CI, 1.168-2.570) and tumour thrombosis (hazard ratio, 0.323; 95% CI, 0.141-0.742) were independent risk factors significantly associated with OS.

Conclusions: Preoperative TACE is related to improving PFS and OS after resection of HCC. Preoperative TACE and tumour thrombus volume were also found to be independent risk factors associated with OS.

Citing Articles

Enhanced prediction of 5-year postoperative recurrence in hepatocellular carcinoma by incorporating LASSO regression and random forest models.

Su B, Zhu C, Cao J, Peng R, Tu D, Jiang G Surg Endosc. 2025; .

PMID: 40032663 DOI: 10.1007/s00464-025-11631-6.

References

Kaibori M, Tanigawa N, Kariya S, Ikeda H, Nakahashi Y, Hirohara J . A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci. 2012; 57(5):1404-12. DOI: 10.1007/s10620-012-2029-3. View

Zhang Y, Guo R, Zou R, Shen J, Wei W, Li S . Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol. 2015; 26(7):2078-88. DOI: 10.1007/s00330-015-4021-8. View

Ahn K, Kang K . Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?. Clin Mol Hepatol. 2019; 25(4):354-359. PMC: 6933127. DOI: 10.3350/cmh.2018.0096. View

Lencioni R, De Baere T, Soulen M, Rilling W, Geschwind J . Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016; 64(1):106-16. DOI: 10.1002/hep.28453. View

Wang X, Yuan Y, Wang J, Liu Z, Chen M, Zhou Q . Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma. J Cancer. 2021; 12(20):6231-6241. PMC: 8425190. DOI: 10.7150/jca.55806. View

Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y . Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004; 139(7):766-74. DOI: 10.1001/archsurg.139.7.766. View

Yang Y, Lin K, Liu L, Qian Y, Yang Y, Yuan S . Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis. Cancer Med. 2021; 10(6):2100-2111. PMC: 7957201. DOI: 10.1002/cam4.3814. View

Lim K, Chow P, Allen J, Siddiqui F, Chan E, Tan S . Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg. 2012; 99(12):1622-9. DOI: 10.1002/bjs.8915. View

Chen X, Hu D, Zhang Z, Zhang B, Chen Y, Zhang W . Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma. Dig Surg. 2007; 24(3):208-13. DOI: 10.1159/000102901. View

10.

Grazi G, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A . Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001; 234(1):71-8. PMC: 1421950. DOI: 10.1097/00000658-200107000-00011. View

11.

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

12.

Chua T, Liauw W, Saxena A, Chu F, Glenn D, Chai A . Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2009; 30(2):166-74. DOI: 10.1111/j.1478-3231.2009.02166.x. View

13.

Lu W, Li Y, He X, Mo Y, Zhu Z . Transcatheter arterial chemoembolization enhances expression of Nm23-H1 and TIMP-2 in the tumor tissue of patients with hepatocellular carcinoma. Hepatogastroenterology. 2011; 58(106):558-64. View

14.

Sasaki A, Iwashita Y, Shibata K, Ohta M, Kitano S, Mori M . Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol. 2006; 32(7):773-9. DOI: 10.1016/j.ejso.2006.04.002. View

15.

Kang J, Choi M, Kim S, Kil J, Lee J, Koh K . Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol. 2011; 16(4):383-8. PMC: 3304614. DOI: 10.3350/kjhep.2010.16.4.383. View

16.

Ren Z, Yue Y, Zhang Y, Dong J, Liu Y, Yang X . Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles. Front Immunol. 2021; 12:624789. PMC: 7943450. DOI: 10.3389/fimmu.2021.624789. View

17.

Xu X, Liu X, Liang M, Luo B . Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology. 2017; 287(2):461-472. DOI: 10.1148/radiol.2017162756. View

18.

Doyle A, Gorgen A, Muaddi H, Aravinthan A, Issachar A, Mironov O . Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019; 70(5):866-873. DOI: 10.1016/j.jhep.2018.12.027. View

19.

Ha T, Hwang S, Lee Y, Kim K, Ko G, Ii Gwon D . Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma. World J Surg. 2015; 40(5):1200-10. DOI: 10.1007/s00268-015-3373-1. View

20.

Benedetto U, Head S, Angelini G, Blackstone E . Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg. 2018; 53(6):1112-1117. DOI: 10.1093/ejcts/ezy167. View